Epigenetic molecular signatures as biomarkers in neurodegenerative diseases
Integration of multiomic data is driving the development of cell-type-resolved reference atlases and molecular signatures of neurodegeneration.
Next-generation epigenetic editors are enabling causal interrogation of disease associated marks, revealing disease driving and potentially modifiable epigenetic mechanisms.
Altered chromatin architecture and global epigenomic dysregulation are emerging hallmarks of neurodegenerative diseases, detectable not only in the brain but also in peripheral biofluids.
Peripheral chromatin accessibility and conformation signatures are emerging as clinically actionable biomarkers for early diagnosis, prognosis, and stratification.
Circulating DNA (hydroxy-)methylation profiles offer new avenues for noninvasive biomarker discovery for neurodegenerative diseases, but low yield and sensitivity in detecting neuronal signals remain key challenges.
https://www.cell.com/trends/neurosciences/fulltext/S0166-2236(26)00050-0
https://sciencemission.com/Epigenetic-biomarkers-in-ND
